Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 3, 2010, Pages 559-566

  Loupakis, Fotios ^a   Masi, Gianluca ^a   Fornaro, Lorenzo ^a   Vasile, Enrico ^a   Allegrini, Giacomo ^b   Fontana, Eloise ^b   Granetto, Cristina ^c   Salvatore, Lisa ^a   Mentuccia, Lucia ^d   Andreuccetti, Michele ^a   Cortesi, Enrico ^d   Merlano, Marco ^c   Cascinu, Stefano ^e   Falcone, Alfredo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c S CROCE E CARLE HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

5 Fluorouracil; Cisplatin; Docetaxel; Gastric cancer; Irinotecan; Sequential chemotherapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; FLUOROURACIL PLUS FOLINIC ACID; IRINOTECAN; OXALIPLATIN; UNCLASSIFIED DRUG; CAMPTOTHECIN; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID; TAXOID;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMACH ADENOCARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; DRUG EFFECT; ESOPHAGUS TUMOR; LOWER ESOPHAGUS SPHINCTER; METASTASIS; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 77954678709     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1196-1     Document Type: Article

References (21)

1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137-2150
2. Van Cutsem E, Van de Velde C, Roth A et al (2008) Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European organisation for research and treatment of cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 44:182-194
3. Catalano V, Labianca R, Beretta GD et al. (2009) Gastric cancer. Crit Rev Oncol Hematol 71:127-164
4. Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909
5. Ajani JA (2006) Standard of care for gastric cancer based on meta-analysis? Treading on thin ice or it is very nice!. J Clin Oncol 24:5473-5474 author reply 5474-5476
6. Wong R, Cunningham D (2009) Optimising treatment regimens for the management of advanced gastric cancer. Ann Oncol 20:605-608
7. Dank M, Zaluski J, Barone C et al (2008) Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19:1450-1457
8. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24:4991-4997
9. Wagner AD, Wedding U, Kuss O, Hoffken K (2007) Docetaxel for advanced gastric cancer? J Clin Oncol 25:2490-2491 author reply 2491-2493
10. Ilson DH (2007) Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol 25:3188-3190
11. Cascinu S, Graziano F, Barni S et al (2001) A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. Br J Cancer 84:470-474
12. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92:205-216
13. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
14. Kang YK, Kang WK, Shin DB et al (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20:666-673
15. A study of bevacizumab in combination with capecitabine and cisplatin as first-line therapy in patients with advanced gastric cancer. Source: www.cancer.gov. Accessed 15 Sep. 2009
16. Erbitux in combination with xeloda and cisplatin in advanced esophago-gastric cancer. Soruce: www.cancer.gov. Accessed 15 Sep. 2009
17. Bouche O, Raoul JL, Bonnetain F et al (2004) Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 22:4319-4328
18. Moehler M, Eimermacher A, Siebler J et al (2005) Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 92:2122-2128
19. Lorenzen S, Hentrich M, Haberl C et al (2007) Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 18:1673-1679
20. Tebbutt N, Sourjina T, Strickland A et al. (2007) ATTAX: Randomised phase II study evaluating weekly docetaxel-based chemotherapy combinations in advanced esophago-gastric cancer, final results of an AGITG trial. J clin Oncol, ASCO Annual Meeting Proceedings 25:4528
21. Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46